Pentamidine dihydrochloride NEW
Price | $50 | $75 | $128 |
Package | 5mg | 10mg | 25mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Pentamidine dihydrochloride | CAS No.: 50357-45-4 |
Purity: 98.58% | Supply Ability: 10g |
Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Pentamidine dihydrochloride |
Description | Pentamidine dihydrochloride (MP-601205 dihydrochloride) is an aromatic diamidine agent effective against various microorganisms, including protozoa (Trypanosoma brucei, Leishmania spp., and Babesia spp.) and fungi (Pneumocystis jirovecii). It is a potent and selective inhibitor of protein tyrosine phosphatases and phosphatase of regenerating liver. Pentamidine dihydrochloride inhibits the parasite Leishmania infantum with an IC50 of 2.5 μM. |
In vitro | Pentamidine at its therapeutic doses inhibited recombinant PRL phosphatases in vitro and inactivated ectopically expressed PRLs in NIH3T3 transfectants with an effective duration more than 24 h after a pulse cell treatment[3]. |
In vivo | Pentamidine at a tolerable dose markedly inhibited the growth of WM9 human melanoma tumors in nude mice coincident with the induction of tumor cell necrosis and is capable of inactivating ectopically expressed PRL-2 in the cancer cells[3]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 4.13 mg/mL (10 mM), Sonication is recommended. |
Keywords | PTP1B | Pneumocystis | Parasite | Antibiotic | Pentamidine | MP601205 | antitumor | Inhibitor | Kidney | carinii | Bacterial | cell-cycle | pneumonia | Phosphatase | inhibit | MP 601205 | MP-601205 | DNA | Pentamidine dihydrochloride | MP 601205 Dihydrochloride | MP601205 Dihydrochloride | Pentamidine Dihydrochloride | biosynthetics | MP-601205 Dihydrochloride | Fungal | arrest |
Inhibitors Related | Neomycin sulfate | Kanamycin sulfate | Sulfamethoxazole sodium | Hydroxychloroquine | Doxycycline | Dimethyl sulfoxide |
Related Compound Libraries | Anti-Parasitic Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Anti-Fungal Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
$10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-06 | |
$0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY